Dantron

Dantron

File:Dantron.svg
Clinical data
Routes of administration	Oral, rectal (enema)
ATC code	A06AB03 (WHO) A06AB53 (WHO) A06AG03 (WHO)
Identifiers
IUPAC name 1,8-dihydroxyanthracene-9,10-dione
CAS Number	117-10-2
PubChem CID	2950
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C14H8O4
Molar mass	240.211 g/mol

WikiDoc Resources for Dantron
Articles
Most recent articles on Dantron Most cited articles on Dantron Review articles on Dantron Articles on Dantron in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Dantron Images of Dantron Photos of Dantron Podcasts & MP3s on Dantron Videos on Dantron
Evidence Based Medicine
Cochrane Collaboration on Dantron Bandolier on Dantron TRIP on Dantron
Clinical Trials
Ongoing Trials on Dantron at Clinical Trials.gov Trial results on Dantron Clinical Trials on Dantron at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Dantron NICE Guidance on Dantron NHS PRODIGY Guidance FDA on Dantron CDC on Dantron
Books
Books on Dantron
News
Dantron in the news Be alerted to news on Dantron News trends on Dantron
Commentary
Blogs on Dantron
Definitions
Definitions of Dantron
Patient Resources / Community
Patient resources on Dantron Discussion groups on Dantron Patient Handouts on Dantron Directions to Hospitals Treating Dantron Risk calculators and risk factors for Dantron
Healthcare Provider Resources
Symptoms of Dantron Causes & Risk Factors for Dantron Diagnostic studies for Dantron Treatment of Dantron
Continuing Medical Education (CME)
CME Programs on Dantron
International
Dantron en Espanol Dantron en Francais
Business
Dantron in the Marketplace Patents on Dantron
Experimental / Informatics
List of terms related to Dantron

Overview

"Dantron" is also a trade name of ondansetron, an unrelated drug, in South Africa.

Dantron (also known as chrysazin) is an anthraquinone derivative, 1,8-dihydroxyanthraquinone, used in some countries as a stimulant laxative. In the USA it is considered to be a carcinogen, and is therefore not used. In the UK it is considered a possible carcinogen and so its licence is restricted to patients who already have a diagnosis of terminal cancer (i.e. it is mainly used in palliative care to counteract the constipating effects of opioids)

It has the notable side-effect of causing red-coloured urine.

"Danthron" was the British Approved Name, but it has now been changed to "dantron" in harmony with the recommended International Nonproprietary Name (rINN).